DF/HCC Program Affiliation

Cancer Epidemiology
Breast Cancer, Leader

DF/HCC Associations

Member, Center Scientific Council
Principal Investigator, Breast Cancer SPORE
Member, Clinical Science Coordinating Committee

Research Abstract

I am working in the area of breast cancer genetics, both at a biological and clinical level. Clinically, I am interested in the application of genetic susceptibility testing in actual practice. More fundamentally, I am interested in the genes which confer susceptibility to breast cancer. Previous work has focused on BRCA1 and BRCA2, but future investigation will be directed toward the role of DNA damage and breast cancer risk.

Publications

• Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP.Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early bre
  17317830
• Chang SB, Miron P, Miron A, Iglehart JD.Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.J Surg Res 2007 Mar;138(1):37-44.
  17109887
• Shi Q, Harris LN, Lu X, Li X, Hwang J, Gentleman R, Iglehart JD, Miron A.Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery.J Proteome Res 2006 Nov;5(11):2947-55.
  17081046
• Biswas DK, Iglehart JD.Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.J Cell Physiol 2006 Dec;209(3):645-52.
  17001676
• Wang ZC, Buraimoh A, Iglehart JD, Richardson AL.Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays.Breast Cancer Res Treat 2006 Apr 27.
  16642273
• Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH.Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data.BMC Bioinformatics 2006;7:197.
  16606446
• Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S.X chromosomal abnormalities in basal-like human breast cancer.Cancer Cell 2006 Feb;9(2):121-32.
  16473279
• Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR.Isolation and initial characterization of the BRCA2 promoter.Oncogene 1999 Oct 28;18(44):6000-12.
  10557089
• Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ.Overestimation of hereditary breast cancer risk.Ann Surg 1998 Sep;228(3):375-84.
  9742920
• Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD.Cell cycle control of BRCA2.Cancer Res 1996 Oct 15;56(20):4590-4.
  8840967
• Iglehart JK.Grassroots activism and the pursuit of an expanded physician supply.N Engl J Med 2008 Apr 17;358(16):1741-9.
  18420508
• Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL.Predicting features of breast cancer with gene expression patterns.Breast Cancer Res Treat 2008 Mar;108(2):191-201.
  18297396
• Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA, Hankinson SE.Circulating colony stimulating factor-1 and breast cancer risk.Cancer Res 2008 Jan 1;68(1):18-21.
  18172291
• Iglehart JK.The fate of SCHIP--surrogate marker for health care ideology?.N Engl J Med 2007 Nov 22;357(21):2104-7.
  17947389
• Iglehart JK.The battle over SCHIP.N Engl J Med 2007 Sep 6;357(10):957-60.
  17804839
• Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA.Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.Cancer Cell 2007 Aug;12(2):160-70.
  17692807
• Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M.Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?.J Surg Oncol 2007 Jul 19.
  17640031
• Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK.Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.M
  17620428
• Iglehart JK.Insuring all children--the new political imperative.N Engl J Med 2007 Jul 5;357(1):70-6.
  17611210
• Qiao M, Iglehart JD, Pardee AB.Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.Cancer Res 2007 Jun 1;67(11):5293-9.
  17545609
• Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL.Serial transplantation of NMU-induced rat mammary tumors: a model of human breast cancer progression.Int J Cancer 2007 Aug 1;121(3):474-85.
  17405122
• Iglehart JK.Biotech drugs come of age; policymakers take notice.Health Aff (Millwood) 2006 Sep-Oct;25(5):1202-3.
  16966714
• Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM.Abnormalities of the Inactive X Chromosome Are a Common Feature of BRCA1 Mutant and Sporadic Basal-like Breast Cancer.Cold Spring Harb Symp Quant Biol 2005;70:93-
  16869742
• Wang ZC, Buraimoh A, Iglehart JD, Richardson AL.Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays.Breast Cancer Res Treat 2006 Jun;97(3):301-9.
  16791486
• Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS.The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.Am J Surg 2006 Jul;192(1):58-62.
  16769276
• Vansonnenberg E, Shankar S, Parker L, Cheung L, Morrison PR, Silverman SG, Igelhart D.Palliative radiofrequency ablation of a fungating, symptomatic breast lesion.AJR Am J Roentgenol 2005 Mar;184(3 Suppl):S126-8.
  15728004
• Chan MM, Iglehart JD.Viral oncolysis: tumor-tailored therapy.Curr Surg 2005 Jan-Feb;62(1):25-30.
  15708137
• Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A.Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.Cancer Res 2004 Jan 1
  14729609
• Nahta R, Iglehart JD, Kempkes B, Schmidt EV.Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.Cancer Res 2002 Apr 15;62(8):2267-71.
  11956082
• Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP.Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ.J Womens Health Gend Based Med 2001 Jul-Aug;10(6):589-98.
  11559456
• Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS.Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.Clin Cancer Res 2001 Jun;7(6):1497-504.
  11410482
• Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K.Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.Cancer Res 2000 Dec 15;60(24):6859-63.
  11156380
• Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR.Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis.J Clin Oncol 1999 May;17(5):1465-73.
  10334532
• Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP.Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.J Clin Oncol 1999 Mar;17(3):1040-6.
  10071299
• Elbendary AA, Cirisano FD, Evans AC, Davis PL, Iglehart JD, Marks JR, Berchuck A.Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.Clin Cancer Res 1996 Sep;2(9):1571-5.
  9816335
• Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR.Complex response of breast epithelial cell lines to topoisomerase inhibitors.Anticancer Res 1998 Jul-Aug;18(4C):2919-32.
  9713486
• Burke HB, Hoang A, Iglehart JD, Marks JR.Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma.Cancer 1998 Mar 1;82(5):874-7.
  9486576
• Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E.Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis.Br J Cancer 1998;77(1):51-6.
  9459145
• Lo JY, Baker JA, Kornguth PJ, Iglehart JD, Floyd CE.Predicting breast cancer invasion with artificial neural networks on the basis of mammographic features.Radiology 1997 Apr;203(1):159-63.
  9122385
• Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD.BRCA1 expression is not directly responsive to estrogen.Oncogene 1997 Jan 9;14(1):115-21.
  9010238
• Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, Marks JR.Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides.Nucleic Acids Res 1996 Nov 1
  8948649
• Hettasch JM, Bandarenko N, Burchette JL, Lai TS, Marks JR, Haroon ZA, Peters K, Dewhirst MW, Iglehart JD, Greenberg CS.Tissue transglutaminase expression in human breast cancer.Lab Invest 1996 Nov;75(5):637-45.
  8941210
• Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD.Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.Oncogene 1996 Sep 19;13(6):1315-22.
  8808706
• Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, Marks JR.BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.Cell Growth Differ 1996 Jun;7(6):711-5.
  8780884
• Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA.BRCA2 mutations in primary breast
  8640235
• Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, Jirtle RL.M6P/IGF2 receptor: a candidate breast tumor suppressor gene.Oncogene 1996 May 2;12(9):2003-9.
  8649861
• Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR.Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.Proc Natl Acad Sci U S A 1995 Aug 29;92(18):8338-42.
  7667291
• Iglehart JD, Kerns BJ, Huper G, Marks JR.Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.Breast Cancer Res Treat 1995 Jun;34(3):253-63.
  7579490
• Weigel RJ, Crooks DL, Iglehart JD, deConinck EC.Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma.Cell Growth Differ 1995 Jun;6(6):707-11.
  7669725
• Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR.A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.Cancer Res 1995 Jan 1;55(1):51-6.
  7805040
• Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barrett JC, Wiseman RW.Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.Cancer Res 1994 Apr 1;54(7):1791-4.
  7511052
• Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD.Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.Ann Surg 1994 Apr;219(4):332-41.
  7909221
• Kerns BJ, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfied LJ.Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.Mod Pathol 1993 Nov;6(6):673-8.
  7905629
• Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR.p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.J Histochem Cytochem 1992 Jul;40(7):1047-51.
  1607637